Business Wire

Tetrate and Federal Agency NIST Cohost ZTA and DevSecOps Conference 2022 Kicking Off With Istio and Envoy Training

Share

Tetrate, the leading company providing a zero-trust application connectivity platform, announced their third annual conference on Zero Trust Architecture (ZTA) and DevSecOps for Cloud Native Applications in partnership with the U.S. National Institute of Standards and Technology (NIST), the federal organization responsible for creating security standards. The NIST–Tetrate multi-cloud conference is a premier event for CISOs, platform architects, and tech leadership from federal and corporate organizations.

The virtual conference will take place on January 27 from 8:00 a.m. – 5:00 p.m. EST and will be preceded by a 2.5-hour training on January 26, showcasing the implementation of Zero Trust Architecture on an actual Platform One deployment. This year’s conference will focus on DevSecOps and ZTA as foundational approaches to developing, deploying, and operating high assurance, cloud native applications. Featured speakers include: André Mendes, Department of Commerce CIO; Kelsey Hightower, Principal Engineer Google Cloud; Ronald Ross, NIST Fellow; and Zack Butcher, Tetrate Founding Engineer. The conference has seen tremendous growth in attendance over the past three years. Past speakers have included Nicolas Chalain, the U.S. Air Force’s first Chief Software Officer, and Zulfikar Ramzan, CTO of RSA Security.

“Cybersecurity incidents are one of the biggest issues facing organizations today, especially as the world moves towards cloud-native applications,” said David Ferraiolo of NIST. “Developing, deploying, and operating zero-trust enabled applications to achieve security, reliability, and resiliency is extremely important for organizations to feel secure.”

“Over the last three years, the NIST–Tetrate conference has featured dialogues and workshops from the world’s most esteemed service mesh and cybersecurity experts," said Varun Talwar, co-founder of Tetrate. "The growth in popularity of the conference is a testament to the importance of ZTA and DevSecOps in a multi-cloud environment. This year, again, we're thrilled to gather together and offer our global community valuable insights and perspectives from top visionaries."

Cloud-native applications often consist of microservices deployed across a combination of public cloud, private cloud, and on-prem, also known as heterogeneous infrastructure. This has created challenges related to connectivity, security, and reliability for delivering high-assurance applications, leading to the popularity of DevSecOps and ZTA. Service mesh plays a critical role in incorporating zero-trust design and DevSecOps principles by adding security and reliability to connect microservices across infrastructures without any additional code.

The conference will feature presentations by domain experts, practitioners, and thought leaders in DevSecOps and Zero Trust Architecture (ZTA) deployments, as well as demonstrations of proof-of-concept use cases in multi-cloud environments. Presentations will address the following:

  • ZTA guiding principles and approaches for workflow, system design, and operations through DevSecOps pipelines, authentication and authorization frameworks, and continuous monitoring;
  • NIST’s latest guidance on DevSecOps and security engineering practices;
  • The role of automation in operational security;
  • The benefits of prescribed approaches, such as prevention of configuration drift and continuous authority to operate.

In addition to a lineup of notable speakers, the training on January 26 will help deliver an educational experience where attendees will learn new skills and cover the deployment of a zero-trust platform with the use of Istio, Kubernetes, and other tools to implement the following security components:

  • in-app and user-level security permissions,
  • encryption in transit,
  • enhanced identity and access controls, and
  • runtime observability.

Tetrate also provides free passes, on request, to application security professionals who need the $35 fee waived.

Join the virtual event: Registration page

  • Join and follow the conversation with hashtag #ZTACon2022 #DevSecOps
  • Twitter: @tetrateio
  • LinkedIn: Tetrate
  • YouTube: Tetrate

For more information regarding ZTA and DevSecOps Conference 2022, an entirely virtual experience taking place this week, please visit: https://www.tetrate.io/zta-devsecops-conference-2022.

About Tetrate–NIST Collaboration

Tetrate and NIST have collaborated over the last three years across multiple deliverables. Using NIST’s experience with cybersecurity and Tetrate’s expertise on secure service mesh, they have collaborated to produce U.S. security standards for a distributed architecture:

About Tetrate

Started by Istio founders to reimagine application networking, Tetrate is an enterprise service mesh company managing the complexity of modern, hybrid cloud application infrastructure. Customers get consistent, baked-in observability, runtime security, and traffic management in any environment. Its flagship product, Tetrate Service Bridge, provides an edge-to-workload application connectivity platform to deliver business continuity, agility, and security for enterprises on the journey from traditional monoliths to the cloud. Tetrate remains a top contributor to the open-source projects Istio and Envoy Proxy. Find out more at www.tetrate.io.

About NIST

The National Institute of Standards and Technology (NIST) was founded by the U.S. Congress in 1901 and is now part of the U.S. Department of Commerce. NIST is one of the nation's oldest physical science laboratories. From the smart electric power grid and electronic health records to atomic clocks, advanced nanomaterials, and computer chips, innumerable products and services today rely in some way on technology, measurement, and standards provided by NIST.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Annie Fink, Bospar
Annie@bospar.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA®▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)19.8.2022 11:30:00 EEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed in the EU for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with fewer than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with progressive and debilitating musculoskeletal deficits,6,7 ultimately having a detr

Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 08:00:00 EEST | Press release

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a

Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis18.8.2022 19:27:00 EEST | Press release

Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis. “DLQ02 evaluates for the first time hyliQTM, a novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “Calcineurin inhibitors for the treatment of psoriasis are a standard of care when given orally, albeit being associated with significant risk for systemic side effects. DLQ02 is designed to overcome the challenges of topical delivery of this drug class with reduced risk profiles. We are convinced DLQ02 has the potential to transform topical psoriasis therapy for millions of patients.” The r

Aero Secures $65M in Series B Financing to Accelerate the Future of Premium Air Travel18.8.2022 19:00:00 EEST | Press release

Aero Technologies, Inc. the next-generation premium air travel company, which serves routes in both the US and Europe, today announced a $65M capital raise, $50M in Series B funding and $15M in convertible notes, for a total post-money valuation of $300M. The funding round was co-led by AlbaCore Capital Group, one of Europe’s leading alternative investment firms, and returning investors Expa and Keyframe Capital, with new investment from Capital One Ventures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005095/en/ (Photo: Business Wire) Inspired by the golden age of aviation and designed for modern life, Aero is redefining semi-private air travel. Aero serves premium leisure travelers through private terminals, enriching the experience with personalized Concierge services - from booking to touchdown. With its fleet of sleek, black planes, Aero offers elevated, effortless guest experiences to curated destinations with

Methane Electrolysis Can Decarbonize LNG/LPG Imports and Achieve EU’s Climate Targets18.8.2022 15:00:00 EEST | Press release

To become independent of Russian natural gas imports by 2027, the European Union is increasing near-term imports of US or Azerbaijan liquefied natural gas (LNG) or liquefied petroleum gas (LPG). The main element of LNG, methane, is the second leading greenhouse gas contributing to climate change. Environmental organizations warn that long-term supply contracts for the fossil LNG will undermine the European Green Deal. The German company Graforce has developed a methane electrolysis technology (plasmalysis) that uses LNG or LPG to produce hydrogen and solid carbon for dioxide-free energy generation. Compared to water electrolysis, plasmalysis requires only one fifth the energy to produce the same amount of hydrogen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005013/en/ Graforce has developed methane electrolysis plants. Errected at LNG terminals or other decentralized locations, they can decarbonize energy supply, a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom